Bora Pharmaceuticals Co., Ltd. has renewed a five-year manufacturing partnership with GSK plc, worth $250 million, extending their collaboration through 2030. Bora acquired the Mississauga facility from GSK in 2020 and will provide manufacturing services for over 20 product lines and 335 individual products. The deal expands GSK’s access to multiple sites within Bora’s network, including the Maple Grove facility in Minnesota. GSK closed trading 0.32% lower at GBp2,206 on the London Stock Exchange, while Bora Pharmaceuticals is currently trading 4.84% higher at TWD 520 on the Taiwan Stock Exchange.

Read more at Nasdaq: Bora Pharmaceuticals Signs $250 Mln Five-Year Manufacturing Deal With GSK; Bora Stock Up